Clinical Trials
2 trialsNCT06090669 2026-06-03
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06124157 2026-06-03
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
Phase 2 Recruiting